Treatment of chronic hepatitis B currently consists of long-term therapy with oral nucleos(t)ide analogues or one year peginterferon injections. Within this thesis, Roeland Zoutendijk explores the long term clinical outcome of the currently most potent nucleos(t)ide analogues entecavir and tenofovir on virological, serological and clinical endpoints within several (inter)national cohort studies. Main findings of this thesis are that adaptation of entecavir therapy does not seem necessary in the majority of patients with a partial virological response at week 48, as prolonged therapy after week 48 leads to undetectable HBV DNA in the majority of patients. In addition, achieving a virological response during entecavir therapy is associated with a lower probability of clinical disease progression (development of HCC, hepatic decompensation and death) in patients with cirrhosis, underlining the importance of achieving this endpoint especially in those with more advanced liver disease.

Additional Metadata
Keywords antiviral therapy, chronic hepatitis B, nucleos(t)ide analogues
Promotor H.L.A. Janssen (Harry)
Publisher Erasmus University Rotterdam
Sponsor Financial support for this thesis was kindly given by the Department of Gastroenterology and Hepatology of the Erasmus MC University Medical Center Rotterdam, de Nederlandse Vereniging voor Hepatologie, Erasmus Universiteit Rotterdam, J.E. Jurriaanse stichting, Abott Diagnostics, Gilead Sciences, Glaxosmithkline, Janssen-Cilag, Roche and Innogenetics.
ISBN 978-94-6169-332-7
Persistent URL hdl.handle.net/1765/38177
Citation
Zoutendijk, R. (2012, December 21). Long-term clinical outcome of antiviral therapy for chronic hepatitis B. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/38177